Drugs / Norditropine SimpleXx®
Norditropine SimpleXx®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00597480 Comparator | Jan 2008 → Jan 2012 | fetal growth restriction | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norditropine SimpleXx | “the recommended dose in the EU of rhGH (Norditropine SimpleXx®)” NCT00597480 ↗ |
| Known as | Recombinant growth hormone | “Recombinant growth hormone (rhGH) treatment is widely used in France to normalize height during childhood and final height in children born small for gestational age (SGA).” NCT00597480 ↗ |
| Known as | rhGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00597480 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant growth hormone (rhGH) treatment” NCT00597480 ↗ |